Fmr LLC Ligand Pharmaceuticals Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Fmr LLC holds 1,960 shares of LGND stock, worth $203,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,960

Previous 1,808 8.41%

Holding current value

$203,212

Previous $132,000 25.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$68.53 - $87.91 $10,416 - $13,362	152 Added 8.41%	1,960 $165,000
Q1 2024 May 13, 2024	SELL	$68.64 - $89.2 $561,818 - $730,102	-8,185 Reduced 81.91%	1,808 $132,000
Q4 2023 Feb 13, 2024	BUY	$49.57 - $72.63 $478,598 - $701,242	9,655 Added 2856.51%	9,993 $713,000
Q3 2023 Nov 13, 2023	SELL	$58.86 - $72.67 $13,008 - $16,060	-221 Reduced 39.53%	338 $20,000
Q2 2023 Aug 11, 2023	SELL	$69.53 - $79.33 $486 - $555	-7 Reduced 1.24%	559 $40,000
Q1 2023 May 11, 2023	BUY	$65.67 - $77.08 $10,244 - $12,024	156 Added 38.05%	566 $41,000
Q4 2022 Feb 13, 2023	SELL	$61.72 - $96.74 $24,564 - $38,502	-398 Reduced 49.26%	410 $27,000
Q3 2022 Nov 10, 2022	BUY	$0.01 - $107.56 $0 - $3,441	32 Added 4.12%	808 $70,000
Q2 2022 Aug 12, 2022	SELL	$74.52 - $117.06 $31,894 - $50,101	-428 Reduced 35.55%	776 $69,000
Q1 2022 May 13, 2022	BUY	$94.99 - $151.56 $74,567 - $118,974	785 Added 187.35%	1,204 $135,000
Q4 2021 Feb 14, 2022	SELL	$127.69 - $165.85 $510 - $663	-4 Reduced 0.95%	419 $64,000
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $71,835 - $101,600	-702 Reduced 62.4%	423 $58,000
Q2 2021 Aug 13, 2021	BUY	$113.03 - $155.64 $127,158 - $175,094	1,125 New	1,125 $147,000

Others Institutions Holding LGND

# of Institutions

247

Shares Held

17.5M

Call Options Held

61K

Put Options Held

7.8K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.75B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account